Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2004

Filing Date
Filed March 15, 2005
Period End
December 31, 2004
Security
IDXX
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Material agreement8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed March 15, 2005. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' FY2004 10-K shows a strong year driven by its Companion Animal Group (CAG), which generated 82%a of revenue.

Total revenue rose 15.4% to $549.2 millionb (12.3% excluding currency effects), gross margin expanded to 50.8% from 48.4%, and operating income grew 34% to $108.0 million, lifting operating margin to 19.7% from 16.9%. Diluted EPS reached $2.19 versus $1.59 in 2003, and net income climbed to $78.3 million. Growth was broad-based, with laboratory and consulting services (+25%), instruments and consumables (+12%), and rapid assays (+13%) leading, though management noted that some 2004 comparisons were flattered by lower distributor inventory levels in 2003 and favorable currency movements.

The balance sheet and capital allocation picture is more mixed. Cash and investments fell to $157.0 millionc from $255.8 million because the company spent $128.8 million repurchasing about 2.4 million shares and $53.9 million on acquisitions, including Vet Med Lab in Germany, Bommeli AG in Switzerland, and an Ohio laboratory. Goodwill and intangibles nearly doubled to $124.5 million, and stockholders' equity declined to $397.7 million.

Operating cash flow remained robust at $95.4 milliond, though it fell from $117.2 million in 2003. Management guided to slower growth in pharmaceuticals and Water in 2005, a margin headwind from expensing stock compensation starting July 2005 (about $8.0 million pre-tax for 2005), and integration costs from recent acquisitions.

Key risk areas for investors include concentration in distributor purchasing patterns, a fixed-price minimum purchase commitment of $131.8 million for VetTest slides from Ortho through 2010, sole-source supply dependencies, the pending FDA review of the tilmicosin product, and the dependence of the Food Diagnostics Group on international BSE testing demand. The company reported no material legal proceedings and effective internal controls, with PricewaterhouseCoopers issuing an unqualified opinion.

Key Highlights

  1. Revenue grew 15.4% to $549.2 million in 2004, with 12.3% growth after excluding currency effects, led by CAG at $448.7 million (+16.7%).
  2. Gross margin expanded roughly 240 basis points to 50.8%, driven by CAG productivity gains, LaserCyte service cost reductions, and a favorable Ortho slide pricing benefit that management expects to improve further from 2006.
  3. Operating income rose 34.4% to $108.0 million (19.7% margin vs. 16.9%), and diluted EPS increased to $2.19 from $1.59.
  4. The company repurchased 2.4 million shares for $128.8 million, reducing cash and investments to $157.0 million from $255.8 million, and has no dividend policy.
  5. Acquisitions totaling about $53.9 million (Vet Med Lab, Dr. Bommeli AG, and an Ohio lab) added goodwill and intangibles that raised the total to $124.5 million, and management expects Vet Med Lab to contribute $20-25 million in incremental 2005 sales.
  6. Management expects slower growth in pharmaceuticals and Water in 2005, and expects CAG operating expense ratios to rise due to added personnel and acquisition integration costs.
  7. Stock option expensing under SFAS 123(R) begins July 1, 2005, with management estimating about $8.0 million in pre-tax expense for 2005.

Frequently Asked Questions

  1. What drove IDEXX's strong 2004 revenue and profit growth?

    Growth came mainly from the Companion Animal Group, where laboratory and consulting services rose 25% on higher testing volume and acquisitions, and instruments and consumables rose 12% on a larger installed base of VetTest and LaserCyte systems. Margin improvement came from manufacturing and service efficiencies and a favorable currency impact. Part of the reported growth also reflected lower distributor inventory levels in 2003, which management said flattered 2004 comparisons.

  2. How much cash did IDEXX return to shareholders, and how does that affect its financial flexibility?

    IDEXX spent $128.8 million repurchasing about 2.4 million shares at an average price of $53.37 in 2004, and it has repurchased 11.96 million shares cumulatively under a 14 million share authorization. Combined with acquisitions, this drew cash and investments down by about $99 million to $157.0 million. Working capital fell to $201.6 million. Operating cash flow of $95.4 million still covers capital expenditures of about $29 million, but cash cushion is thinner than in 2003.

  3. What are the biggest risks in IDEXX's supply chain and product pipeline?

    The company is committed to minimum VetTest slide purchases of $131.8 million from Ortho through 2010, at fixed prices, which could create losses if demand falls short or if slide prices cannot be passed through to customers. Several key products are sole-sourced, including VetTest, QBC, VetLyte, and VetStat components, along with the Navigator active ingredient. The next-generation chemistry analyzer is not expected before 2006, and the long-acting tilmicosin product awaits FDA approval, not expected before 2006.

  4. What is the outlook for IDEXX's Food Diagnostics Group and the BSE testing opportunity?

    The FDG segment grew 6% to $47.4 million in 2004, with 73% of its sales coming from outside the U.S. The company received USDA approval for its postmortem BSE test in 2004 and European Commission approval in February 2005. Management believes the EU runs roughly 10 million tests annually and expects the HerdChek BSE test to drive growth in 2005. However, U.S. BSE testing remains limited, and the outlook depends on regulatory decisions that are outside IDEXX's control.

  5. Does the 10-K disclose any material legal or regulatory issues?

    The company states it is not a party to any material legal proceedings. It does disclose ongoing regulatory obligations, including an FDA agreement covering lot release and stability testing for its SNAP beta-lactam dairy products, which could lead to recalls or sales restrictions if lots fail. It also notes that third parties have sent patent infringement notices in the past, and that a 2004 claim was resolved with a $1.8 million benefit to cost of revenue.